7-11 line point折抵的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列問答集和資訊懶人包

環狀核糖核酸hsa_circ_0000190會促進非小細胞肺癌的發生並透過調升分泌之PD-L1而影響腫瘤逃脫免疫系統

為了解決7-11 line point折抵的問題，作者羅永鴻 這樣論述：

中文摘要................................................i英文摘要................................................ii目錄....................................................iv圖目錄..................................................vii表目錄..................................................viii第一章 緒論.................

............................1第二章 研究目的.........................................4第三章 研究方法.........................................53.1 Patient Population.................................53.2 Cell Culture.......................................63.3 RNA Isolation and qRT-PCR..........................63.4

qRT-PCT and RT-ddPCR for Detecting Plasma circRNA..73.5 RNA-Seq............................................83.6 Cell and Plasmid Preparation for Overexpressing Circular RNA....................................................83.7 Transfection with Small-Interfering RNA (siRNA)....93.8 Cell Prolifera

tion Assay...........................93.9 Migration and Invasion.............................93.10 Wound-Healing Assay...............................103.11 Animal Experiments................................103.12 Western Blotting Analysis.........................113.13 RNA Extraction and RT-qPCR....

....................123.14 Enzyme-Linked Immunosorbent Assay.................133.15 Evaluation of LC Treatment Efficacy...............133.16 Statistical Analysis..............................13第四章 結果.............................................144.1 Identification of Potential Secretory circRNA Biom

arker Candidates Using RNA-Seq...............................144.2. Validation of Expression of hsa_circ_0000190 and hsa_circ_0001649 in LC Cell Lines......................174.3 RT-ddPCR Detection of hsa_circ_0000190 and hsa_circ_0001649 Secreted by LC Cell Lines and in Human Blood Plasma...........

......................................194.4 Expression of hsa_circ_0000190 and hsa_circ_0001649 in LC Patients with Different Stages and Tumor Sizes.........214.5 Plasma Levels of Hsa_circ_0000190 Negatively Correlate with the Response to Immunotherapy.....................254.6 Monitoring the Treatm

ent Response by Plasma Levels of circRNAs in LC Patients Receiving Immunotherapy........284.7 Bioinformatics Analysis of Potential Downstream Network for Hsa_circ_0000190 and Hsa_circ_0001649 in LC........314.8 Overexpression of hsa_circ_0000190 Promoted Tumorigenesis of NSCLC In Vitro..............

........................324.9 Knockdown of hsa_circ_0000190 Hindered Tumorigenesis of NSCLC In Vitro.........................................354.10 Overexpression of C190 Enhanced Tumor Growth In Vivo...................................................374.11 Nanoparticle-Wrapped, siRNA-Mediated C190

Knockdown Inhibited Tumor Growth In Vivo.........................394.12 Interaction among hsa_circ_0000190, microRNA, and Various Immune Checkpoints.............................414.13 PD-L1, CD155, CD80, FGL1, and CD70 Were Expressed in A549 Cells.............................................434.14 O

verexpression of hsa_circ_0000190 Regulated Expression of Immune Checkpoints In Vitro.........................434.15 The Overexpression of hsa_circ_0000190 Promoted Expression of Specific Immune Checkpoint mRNAs in NSCLC Cells..................................................434.16 The Knockdown of

hsa_circ_0000190 by siRNA Impeded Expression of Specific Immune Checkpoint mRNAs in NSCLC Cells..................................................454.17 Overexpression of hsa_circ_0000190 Increased the Expression and Secretion of Soluble PD-L1 in NSCLC Cell Lines and May Be Associated with Decreased

Efficacy of Anti-PD-1 Antibody...............................................47第五章 討論.............................................49第六章 結論.............................................52參考文獻................................................53附錄....................................................63

The Financial Implications of CSR: The Linear and Non-Linear Relationship Between CSR and Firm Performance and the Role of Governance

為了解決7-11 line point折抵的問題，作者何芳庭 這樣論述：

CSR initiatives are becoming more widespread as stakeholders emphasize their importance in both developed and developing countries. CSR is regarded as a necessity for survival and a requirement for remaining competitive. However, as CSR entails substantial costs and consumes valuable resources, the

financial implications are a matter of concern to businesses. Yet, there is still no consensus on the direction of the relationship. The inconclusive pattern could point to a more complex mechanism than simple linear correlations. Specifically, the relationship may be non-linear.The relationship be

tween CSR and firm performance of firms in Asia-Pacific is investigated in this study. The effect of governance at the firm and country levels is also examined. This study employs two main firm performance measures, namely accounting-based and market-based performance. The accounting-based measures

include return on assets (ROA) and return on equity (ROE), while the market-based measures include price-to-book ratio (PBV) and Tobin’s q (TOBIN). To reflect expected differences in CSR initiatives and institutional determinants, a sample of 660 firm-year observations were selected from publicly li

sted firms in 11 Asia-Pacific countries from 2019 to 2020.This study provides evidence of the non-linear link between CSR and firm performance, particularly on the relationship between environmental initiatives and market-based measures of firm performance. The non-linearity is also revealed to be p

ronounced for smaller firms. Furthermore, the findings indicate that the CSR-firm performance relationship is moderated by governance. While some governance mechanisms flatten the relationship, others steepen it, causing both the negative and positive effects to be more pronounced.In order to motiva

te businesses to pursue socially desirable activities while avoiding negative impacts, it is imperative to find the optimal level between the benefits of investments and the costs associated with them. Given that CSR initiatives may not pay off immediately and that the relationship between CSR and f

irm performance is not linear, considerable resources and long-term planning should be devoted to this area.